Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

NCT02879162 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT02879162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02879162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2016
Completion date
January 29, 2025
Enrollment
140 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced rare tumours